title: Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
abstract: OBJECTIVE
  To review the clinical trials literature on the use of antiepileptic drugs (AED) as mood stabilizers and to suggest an evidence-based approach when utilizing these agents in bipolar disorder.
  
  
  METHODS
  The literature is reviewed and subdivided into the following sections: carbamazepine and oxcarbazepine, valproate, lamotrigine, gabapentin and other AED, and discussion.
  
  
  RESULTS
  Data exist to support the use of carbamazepine and valproate - and to a lesser extent, oxcarbazepine - in the management of acute manic episodes associated with bipolar I disorder. Lamotrigine, gabapentin, and other AED have not demonstrated consistent anti-manic effects. Clinical trials data favor lamotrigine over all other AED in the treatment of acute bipolar I depression and in rapid cycling bipolar disorder (particularly type II), although the absence of an active comparator in these lamotrigine trials must be noted. Lamotrigine, carbamazepine, and valproate all have evidence supporting their roles as potential long-term mood stabilizers to prevent bipolar relapse, with lamotrigine having a stronger effect in the prevention of depression.
  
  
  CONCLUSIONS
  The AED are a heterogeneous group of medications with differential spectrum of efficacy in the treatment of bipolar disorder.
authors.affiliation: Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland Clinic Lerner College of Medicine, Case University, OH, USA. muzinad@ccf.org
authors.forename: D J
authors.initials: DJ
authors.lastname: Muzina
authors.forename: O
authors.initials: O
authors.lastname: Elhaj
authors.forename: P
authors.initials: P
authors.lastname: Gajwani
authors.forename: K
authors.initials: K
authors.lastname: Gao
authors.forename: J R
authors.initials: JR
authors.lastname: Calabrese
mesh_terms: D000208:Acute Disease; D000588:Amines / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D000078330:Oxcarbazepine; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D014227:Triazines / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
chemical_list: D000588:Amines; D000927:Anticonvulsants; D018692:Antimanic Agents; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D000077213:Lamotrigine; D000078330:Oxcarbazepine